Long-term follow-up of a phase 3 clinical trial of inolimomab for the treatment of primary steroid refractory aGVHD

TO THE EDITOR: We previously reported the results of the INO107 study,[1][1] a phase 3 randomized, open-label, multicenter study comparing inolimomab (an anti-CD25 monoclonal antibody blocking interleukin-2 receptor α) vs antithymocyte globulin (ATG) in adult patients with steroid-refractory acute